CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Boehringer Ingelheim GmbH is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Boehringer Ingelheim GmbH
Bingerstrasse 173
INGELHEIM AM RHEIN, 55216  Germany
This is a Subsidiary, click here for the Parent Company
Business Summary
Boehringer Ingelheim GmbH is a Germany-based company that develops and manufactures pharmaceuticals for human and animal health. It offers prescription medicines in the areas of benign prostate hyperplasia, cardiovascular disease, chronic obstructive pulmonary disease, diabetes, acute ischaemic stroke, stroke prevention in atrial fibrillation, and venous thromboembolism indications, among other. The Company also provides consumer health products primarily under the Antistax, Bisolvon, Buscopan, Dulcolax, Mucoangin, Mucosolvan, Pharmaton, Thomapyrin, and Zantac brand names; and animal health products, such as biologicals, pharmaceuticals, and natural care products for swine, cattle, small animals, and horses, as well as develops and produces biopharmaceuticals. It operates through a group of 145 affiliates worldwide.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202212/31/2022Yes---Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board of Managing Directors HubertusVon Baumbach 1/1/2022 1/1/2022
Member of the Board of Managing Directors ShashankDeshpande
Member of the Board of Managing Directors FrankHubler
Member of the Board of Managing Directors CarinneKnoche- Brouillon
Member of the Board of Managing Directors MichaelSchmelmer 59

Business Names
Business Name
BEN VENUE
BEN VENUE LABORATORIES INC
Boehringer Ingelheim Vetmedica, Inc.
14 additional Business Names available in full report.

General Information
Number of Employees: 53,155 (As of 12/31/2022)


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024